2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. p38 MAPK

p38 MAPK

p38 MAPK

Related Products

PDF 1.54 MB

The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). It is well known that p38 is involved in inflammation, apoptosis, cardiomyocyte hypertrophy and cell differentiation.

The p38 MAPK family is composed of four proteins: p38α (encoded by the gene Mapk14), p38β (Mapk11), p38γ (Mapk12), and p38δ (Mapk13). Their coding genes have a distinct tissue distribution and they appear differentially expressed, being Mapk14 the most highly expressed. p38 MAPKs are substrates for three MAP2K (MKK6, MKK3, and MKK4). The contribution of each of these MAP2K to p38 MAPKs activation depends on the stimulus and the cell type. The MAP3Ks that lead to p38 MAPKs activation are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1.

p38 MAPK Isoform Specific Products:

p38 MAPK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13478
    AS1940477
    		Inhibitor
    AS1940477 (Compound 3f) is an orally active p38 MAPK inhibitor. AS1940477 inhibits the enzymatic activity of recombinant p38α and β isoforms. AS1940477 inhibits the production of pro-inflammatory cytokines (including TNFα, IL-1β, and IL-6) in human synovial interstitial cells and animal models of inflammation. AS1940477 can be used in research on inflammatory diseases.
    AS1940477
  • HY-119831
    Rohitukine
    		Inhibitor
    Rohitukine is an orally active CDK9/T1 inhibitor with an IC50 of 0.3 μM. Rohitukine blocks ATP binding sites of CDK2/A and CDK9/T1, suppresses PPARγ, AKT, mTOR, C/EBPα, SREBP-2, and NF-κB signaling, and increases hepatic LXRα expression. Rohitukine induces S-phase cell cycle arrest, ROS generation, apoptosis, and exhibits anti-inflammatory activity. Rohitukine can be used for the research of leukemia, pancreatic cancer, prostate cancer, breast cancer, CNS cancer, ovarian cancer, lung cancer, dyslipidemia, inflammatory diseases, inflammatory bowel disease, and arthritis.
    Rohitukine
  • HY-N10119
    Ganoderterpene A
    		Inhibitor
    Ganoderterpene A attenuates LPS-induced inflammation and apoptosis via suppressing MAPK and TLR-4/NF-κB pathways in BV-2 cells.
    Ganoderterpene A
  • HY-P11114
    Periplanetasin-4
    		Inhibitor
    Periplanetasin-4 is an antimicrobial peptide that can be derived from the American cockroach (Periplaneta americana). Periplanetasin-4 reduces cell rounding and apoptosis. Periplanetasin-4 blocks Clostridium difficile toxin A-induced ROS production and the activation of downstream p38 MAPK and p21. Periplanetasin-4 significantly increases mitochondrial calcium level, reduces DPH fluorescence intensity and vacuolar dysfunction in Candida albicans ATCC 90028 cells. Periplanetasin-4 significantly ameliorates toxin A-induced mucosal damage in the mouse gut. Periplanetasin-4 can be used for the study of colitis.
    Periplanetasin-4
  • HY-P1181
    Pam2CSK4
    		Activator
    Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
    Pam2CSK4
  • HY-160215A
    GFH018 methylbenzenesulfonate
    		Inhibitor
    GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma.
    GFH018 methylbenzenesulfonate
  • HY-N17458
    N-Acetyldehydroanonaine
    		Ligand
    N-Acetyldehydroanonaine is an alkaloid that acts as a ligand for AKT1 and MAPK1. N-Acetyldehydroanonaine can be isolated from plants of the Zanthoxylum genus. N-Acetyldehydroanonaine is applicable to the research of diseases such as gastric cancer.
    N-Acetyldehydroanonaine
  • HY-P3395A
    Catestatin sCst
    		Control
    Catestatin sCst is a negative control peptide with a scrambled amino acid sequence. Catestatin sCst fails to activate human mast cells and is used to verify the specificity of Catestatin action.
    Catestatin sCst
  • HY-N6908R
    Continentalic acid (Standard)
    		Modulator
    Continentalic acid (Standard) is the analytical standard of Continentalic acid (HY-N6908). This product is intended for research and analytical applications. Continentalic acid is a diterpenoid organic acid. Continentalic acid exhibits multiple activities including anti-inflammatory, antioxidant, neuroprotective, antibacterial and antitumor effects. Continentalic acid alleviates oxidative stress, reduces pro-inflammatory cytokine production, inhibits MAPK phosphorylation and neutrophil infiltration, and induces growth inhibition and apoptosis of cancer cells. Continentalic acid can be used in research related to traumatic brain injury, cancer, inflammation and infections.
    Continentalic acid (Standard)
  • HY-184250
    FGFR-IN-28
    		Inhibitor
    FGFR-IN-28 is a FGFR inhibitor with inhibitory activity against multiple subtypes of the FGFR family, with an IC50 of 4.4 nM against FGFR4. FGFR-IN-28 inhibits kinase activity and phosphorylation processes, and blocks the downstream MAPK and AKT signaling pathways. FGFR-IN-28 induces cellular DNA damage, cell cycle arrest, apoptosis and ferroptosis, and reduces the adhesion, invasion and metastasis abilities of cancer cells. FGFR-IN-28 exhibits anti-tumor activity in in vitro experiments on colon cancer cells, and inhibits tumor growth in colon cancer xenograft models. FGFR-IN-28 can be used in colon cancer-related research.
    FGFR-IN-28
  • HY-18754
    FR 167653 free base
    		Inhibitor
    FR 167653 free base, an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 free base is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo.
    FR 167653 free base
  • HY-111033
    RO5068760
    		Inhibitor
    RO5068760 is a potent, orally active and selective non-ATP-competitive MEK1/2 inhibitor with an IC50 of 0.025 μM for MEK1. RO5068760 significantly inhibits MAPK pathway activity, thereby inducing G1 cell cycle arrest and apoptosis to inhibit cancer cell growth. RO5068760 exhibits significant efficacy in a broad spectrum of tumors with aberrant MAPK pathway activation. RO5068760 can be used for melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer research.
    RO5068760
  • HY-117152
    L-threo-Sphingosine
    		Inhibitor
    L-threo-Sphingosine is a potent MAPK inhibitor. L-threo-Sphingosine induces apoptosis and clear DNA fragmentation. L-threo-Sphingosine shows anticancer effect.
    L-threo-Sphingosine
  • HY-N2217R
    Rotundic acid (Standard)
    		Activator
    Rotundic acid (Standard) is the analytical standard of Rotundic acid (HY-N2217). This product is intended for research and analytical applications. Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes.
    Rotundic acid (Standard)
  • HY-181817
    (S)-IP-DK143
    		Activator
    (S)-IP-DK143 is a polymeric micellar formulation. (S)-IP-DK143 inhibits the proliferation of cervical cancer cells, induces ROS-mediated apoptosis, and triggers mitochondrial dysfunction. (S)-IP-DK143 activates the p38 MAPK signaling pathway, increases the phosphorylation level of p38. (S)-IP-DK143 can be used for the research of cervical cancer.
    (S)-IP-DK143
  • HY-RS08109
    Mapk14 Rat Pre-designed siRNA Set A
    		Inhibitor

    Mapk14 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mapk14 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Mapk14 Rat Pre-designed siRNA Set A
  • HY-N17888
    Ephemeranthol A
    		Inhibitor
    Ephemeranthol A is a phenanthrene compound with anticancer and anti-inflammatory activities. Ephemeranthol A exerts significant anti-inflammatory effects in macrophages by inhibiting the NF-κB and MAPK signaling pathways. Ephemeranthol A induces apoptosis and inhibits metastasis of lung cancer cells by suppressing the FAK/Akt signaling and EMT processes. Ephemeranthol A can be used for the research of acute and chronic inflammatory diseases and non-small cell lung cancer.
    Ephemeranthol A
  • HY-122967
    Isosalvianolic acid C
    		Activator
    Isosalvianolic acid C is a phenolic compound that can be found in Lavandula angustifolia Mill.. Isosalvianolic acid C can be used as antioxidant.
    Isosalvianolic acid C
  • HY-124487
    GK-136901
    		Inhibitor
    GK-136901 is an orally active, dual Nox1/Nox4 NADPH oxidase inhibitor with a Ki of 160 nM for Nox1 and 165 nM for Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension.
    GK-136901
  • HY-181812
    JNK2/MKK7 PPI-IN-1
    		Inhibitor
    JNK2/MKK7 PPI-IN-1 is an orally active JNK2 inhibitor with an IC50 of 0.99 μM and a Kd of 81.6 μM. JNK2/MKK7 PPI-IN-1 inhibits JNK2 kinase activity, disrupts JNK2-MKK7 protein-protein interaction, and reduces c-Jun phosphorylation. JNK2/MKK7 PPI-IN-1 inhibits LPS-induced overexpression of inflammatory cytokines IL-6 and TNF-α. JNK2/MKK7 PPI-IN-1 can be used for the research of acute lung injury.
    JNK2/MKK7 PPI-IN-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
p38 MAPK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.